Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner
Roche has taken its next big step into the allogeneic CAR-T field, this time tying up alongside Poseida Therapeutics $PSTX with $220 million in upfront and quick cash in a trademark oncology alliance that comes with a mother lode of milestones.
The deal — which includes $110 million for the upfront plus $110 million in near-term cash — offers the pharma giant dibs on a slate of off-the-shelf CAR-Ts for hematologic malignancies, including P-BCMA-ALLO1 for multiple myeloma, now in a Phase I study, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T for the treatment of B-cell malignancies with an IND expected in 2023. But they will also work on more targets together — hammering out new research tech along the way — as the Poseida team takes the lead on early-stage tests and Roche carves out responsibility for the pivotal plays.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.